Back to Articles

Patients with Atrial Fibrillation Find Relief with Rivaroxaban

(Pub. 2nd November 2012)


Rivaroxaban is an oral anticoagulant also known as Xarelto. Rivaroxaban is FDA approved to prevent stroke in people with abnormal heart rhythm, and to prevent deep vein thrombosis, blood clots and pulmonary embolism in patients who have undergone a knee or hip replacement surgery. As an oral option for post-surgical patients, Rivaroxaban is patient preferred when compared to alternate injectable anticoagulants.

Results from the Phase III EINSTEIN-extension study of showed an 82 percent risk reduction for a venous blood clot to form again in patients who had suffered a thrombosis, after they were dosed with Rivaroxaban. The patients who were dosed with Rivaroxaban were compared to patients who received a placebo for a period of between six and twelve months. The once daily dose not only proved to be efficacious, but it also proved to be a safer alternative when compared to Warfarin. There was a 31 percent lower risk of major bleeding in patients who were dosed with Rivaroxaban as compared to patients who were administered Warfarin, as well as an 11 percent reduced risk of patient death.

Another successful study proclaiming the efficacy of Rivaroxaban was titled the EINSTEIN Acute DVT study. In this study Rivaroxaban was deemed not inferior when compared to a combination of the low-molecular-weight heparin Enoxaparin and a vitamin K antagonist. This study was focused on reducing the risk of recurrent deep venous thromboembolism in patients, and  compared Rivaroxaban alone with Enoxaparin, followed by a vitamin K antagonist for the prophylaxis of recurrent VTE or pulmonary embolism. Of the 3,449 patients enrolled in the study, Rivaroxaban was delivered orally in a dose of 15 mg twice daily for 3 weeks, and followed by 20 mg orally once daily for  3, 6, or 12 months. In patients who received Rivaroxaban 8 adverse events occurred among 602 patients who received this drug, as compared with 42 adverse events for the 594 patients treated with the Enoxaparin/vitamin K antagonist regimen. 

On November 2nd, 2012 the FDA expanded the indication for Rivaroxaban to include the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and to reduce the risk of recurrent DVT and PE. In addition, the European Committee for Medicinal Products for Human Use has recommended Rivaroxaban for the treatment of pulmonary embolism and the prevention of recurrent deep vein thrombosis and pulmonary embolism. The decision on approval by the European Commission is expected before the end of the year

With more than two million Americans are afflicted with atrial fibrillation, which leads to a greater risk of stroke for these patients, novel and effective treatments are necessary for the future prevention and care of these patients. Rivaroxaban is in a class of medications called factor Xa inhibitors, which helps to decrease the clotting ability of the blood. This also aids patients who are at risk of stroke or deep vein thrombosis, which can lead to a pulmonary embolism.

YES Pharma is proud to be a leading supply source for Rivaroxaban (CAS#: 366789-02-8, 385766-33-6) to several global pharmaceutical companies and academic research institutes, while recognizing that we play a significant part in the battle for the prevention of strokes, deep vein thrombosis, and pulmonary embolisms. The Rivaroxaban that YES Pharma supplies is intended for laboratory R&D use only.


New England Journal of Medicine :N Engl J Med 2010
P T. 2009 May; 34(5): 238–244.

  • Products currently covered by valid US patents are offered only for laboratory R&D use in accordance with 35 USC 271(e)+A13(1).
  • Any patent infringement and resulting liability is solely at buyer risk.
  • Products covered by valid patents are not offered or supplied for commercial use.


Dun and Bradstreet